TY  - GEN
AU  - Kelly,W K
AU  - Osman,I
AU  - Reuter,V E
AU  - Curley,T
AU  - Heston,W D
AU  - Nanus,D M
AU  - Scher,H I
TI  - The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer
SN  - 1078-0432
PY  - 2000///0601
KW  - Aged
KW  - Antigens, Surface
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biopsy
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Carboxypeptidases
KW  - analysis
KW  - Cheilitis
KW  - chemically induced
KW  - Dyspnea
KW  - Exanthema
KW  - Fatigue
KW  - Glutamate Carboxypeptidase II
KW  - Hematologic Diseases
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Ki-67 Antigen
KW  - Liver
KW  - enzymology
KW  - Male
KW  - Middle Aged
KW  - Prostate
KW  - chemistry
KW  - Prostate-Specific Antigen
KW  - blood
KW  - Prostatic Neoplasms
KW  - Recombinant Proteins
KW  - Transaminases
KW  - drug effects
KW  - Treatment Outcome
KW  - Tretinoin
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S
ER  -